Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01894802
Other study ID # STUDY19100269
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2013
Est. completion date December 2026

Study information

Verified date October 2023
Source University of Pittsburgh
Contact Olivia L Aumiller
Phone 412-648-4192
Email OLA22@pitt.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to demonstrate the safety and efficacy of using two CRS Arrays (microelectrodes) for long-term recording of brain motor cortex activity and microstimulation of brain sensory cortex.


Description:

Individuals with severe paralysis have intact brain function but are unable to move due to injury or disease affecting the spinal cord, nerves or muscles. Brain-machine interface (BMI) technology is based on the finding that with intact brain function, neural (nerve) signals are generated even though they do not reach the arms, hands and legs. By placing (implanting) sensors on the surface of the brain, individuals can be trained to send neural signals which are interpreted by a computer and translated to movement which can then be used to control a variety of devices or computer displays. Using neural activity to control an external device is referred to as a brain-machine interface (BMI) technology. In addition, areas of the brain that are involved in interpreting sensations from the arms, hands and legs remain functional after injury. It is therefore possible to send tiny electrical pulses through implanted arrays to mimic sensory input that would normally come from the arms, hands and legs. The investigators refer to this as "microstimulation."


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 2026
Est. primary completion date August 2025
Accepts healthy volunteers No
Gender All
Age group 22 Years to 70 Years
Eligibility Inclusion Criteria: 1. Subjects must have limited or no ability to use one or both hands due to cervical spinal cord injury, brainstem stroke, brachial plexus injury, above-elbow amputation, or spinal stroke. Individuals with intact limbs must have less than grade 2 strength in finger flexor and abduction on the contralateral side to the implant and a t-score <35 on the PROMIS Upper Extremity Short Form. The non-functional hand(s) may be involved passively in functional tasks; for example, pushing an object or passively grasping an object placed into the hand. However, the participant must report that they have no functional use of their hand(s). 2. Subjects must report that they are unable to perform functional activities with the hand contralateral to implantation. 3. Subjects must be over 1 year post-injury at time of implantation. In addition, subject must report no worsening in neurologic status (strength, sensation) for the previous 6 months. 4. Subjects must be between the ages of 22-70 years old at the time of enrollment and completion of the study. Participants outside this age range may be at an increased surgical risk and increased risk of fatigue during BMI training. 5. Subjects must live within 2 hours of the University of Pittsburgh during the study or be willing to travel to the University of Pittsburgh at least once per week for BMI training. 6. If subjects do not live in the Pittsburgh area, they are expected to stay somewhere within 2 hours of the University of Pittsburgh for at least 18 months after enrollment. 7. Subjects must be able to communicate with the investigators in English because of the need to follow the instructions of the study team. 8. Subjects must show an understanding of the study goals and have the ability to follow simple directions as judged by the investigators 9. Subjects must have results that are within normal limits on neuropsychological and psychosocial assessment; psychosocial health and support will be assessed by interview with the psychologist. 10. Subjects must be able to activate distinct cortical areas during imagined or attempted movement tasks (i.e. hand movement and speaking or moving the mouth); this will be evaluated with functional magnetic resonance imaging (fMRI) as part of screening. 11. Subjects must have a stable psychosocial support and caregivers who are able to perform the necessary daily care of the participant's skin and pedestal site. This requires that the subject identify a caregiver and a backup who have been in place for greater than 6 months and are able to provide needed physical and psychosocial support. This will be assessed by the sponsor-investigator and study neurosurgeon. 12. Subjects must have a life expectancy greater than 18 months as assessed by the study investigator and neurosurgeon sub-investigator 13. Documentation of informed consent must be obtained from the participant or their legal representative. 14. Participants with transhumeral amputation must have been evaluated for a prosthesis, and if deemed appropriate, were fit with an optimized prosthesis. The prosthesis should be used/considered for the PROMIS evaluation. Exclusion Criteria: 1. Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses 2. Another serious disease(s) or disorder(s) that could affect ability to participate in this study (verified during pre-op anesthesia evaluation to determine surgical risk status) 3. Recent history of pressure sores that could be exacerbated by 1-2 days of bed rest 4. Metallic implant(s) that would prohibit the subject from having an fMRI scan; spinal fixators are generally non-ferrous and would not exclude someone from participating in the study 5. Any type of implantable generator such as a pacemaker, spinal cord stimulator, cochlear implant, deep brain stimulator (DBS), DBS leads, vagus nerve stimulator, or defibrillator 6. Women of childbearing age who are pregnant, lactating, or plan to become pregnant during the next 25 months 7. Allergy to contrast medium or kidney failure that could be exacerbated by contrast agent (for MRI) 8. Subjects receiving medications (such as sedatives) chronically that may retard motor coordination and cognitive ability 9. Individuals who require routine MRI, therapeutic ultrasound, or diathermy 10. Individuals with osteomyelitis 11. Severe skin disorder that causes excessive skin sloughing, lesions or breakdown of the scalp 12. History of myocardial infarction or cardiac arrest or with intractable cardiac arrhythmias 13. Individuals with an implanted hydrocephalus shunt 14. Individuals who have had a stroke caused by a surgical procedure 15. Active infection(s) or unexplained fever (verified during pre-op anesthesia evaluation to determine surgical risk status) 16. Consumption of more than 1 alcoholic beverage per day on average 17. Receiving chronic oral or intravenous steroids or immunosuppressive therapy 18. Active cancer within the past year (other than adequately treated basal cell or squamous cell skin cancer) or require chemotherapy 19. Uncontrolled insulin dependent diabetes mellitus 20. Uncontrolled autonomic dysreflexia within the past 3 months (for those with spinal cord injury) 21. Individuals with seizure disorders currently being treated with anti-epileptic medications and individuals with a familial history of seizure disorders 22. Individuals who have attempted suicide in the past 12 months 23. Individuals who are immunosuppressed or who have conditions that typically result in immunocompromise (including, but not limited to: ataxia-telangiectasia, cancer, Chediak-Higashi syndrome, combined immunodeficiency disease, complement deficiencies, DiGeorge syndrome, HIV/AIDS, hypogammaglobulinemia, Job syndrome, leukocyte adhesion defects, malnutrition, panhypogammaglobulinemia, Bruton disease, congenital agammaglobulinemia, selective deficiency of IgA and Wiscott-Aldrich syndrome) 24. Individuals who have had previous neurosurgical intervention involving the frontal lobes (especially the motor cortex) and/or parietal lobe (especially the somatosensory cortex) that is likely to impact the viability of an intracortical electrode 25. Individuals with active psychiatric concerns, including but not limited to major depression, bipolar disorder, schizophrenia or other psychotic disorder and post-traumatic stress disorder 26. Individuals with substance abuse within 6 months of study participation 27. Individuals who are judged by a clinician as being an unsafe ambulator - This would be decided based on a history of frequent uncontrolled falls more than 3 or 4 in a year, or falls that resulted in injury 28. Individuals who plan to participate in contact sports or sports that require a helmet

Study Design


Intervention

Device:
Implantation of CRS Arrays
Two Blackrock Microsystems CRS Arrays will be implanted in the motor cortex and sensory cortex of study participants.

Locations

Country Name City State
United States University of Pittsburgh Pittsburgh Pennsylvania

Sponsors (4)

Lead Sponsor Collaborator
Michael Boninger Carnegie Mellon University, Northwestern University, University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome is the safety of the participant. This measure will be considered a success if the device is not removed for safety reasons during the 12-month post-implant evaluation. One year following array implantation
Secondary The secondary outcome is the efficacy of the electrodes for long-term recording of neural activity and successful control of external devices. The efficacy of the CRS Arrays will be determined through a variety of measures, including characterization of signal quality, degrees of freedom achieved and subject performance. One year following array implantation
See also
  Status Clinical Trial Phase
Recruiting NCT02574572 - Autologous Mesenchymal Stem Cells Transplantation in Cervical Chronic and Complete Spinal Cord Injury Phase 1
Recruiting NCT05941819 - ARC Therapy to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury N/A
Completed NCT05265377 - Safety and Usability of the STELO Exoskeleton in People With Acquired Brain Injury and Spinal Cord Injury N/A
Recruiting NCT02331979 - Improving Bladder Function in SCI by Neuromodulation N/A
Completed NCT02777281 - Safe and Effective Shoulder Exercise Training in Manual Wheelchair Users With SCI N/A
Recruiting NCT02978638 - Electrical Stimulation for Continence After Spinal Cord Injury N/A
Withdrawn NCT02237547 - Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury Phase 1/Phase 2
Completed NCT02262234 - Education Interventions for Self-Management of Pain Post-SCI: A Pilot Study Phase 1/Phase 2
Completed NCT02161913 - Comparison of Two Psycho-educational Family Group Interventions for Persons With SCI and Their Caregivers N/A
Terminated NCT02080039 - Electrical Stimulation of Denervated Muscles After Spinal Cord Injury N/A
Completed NCT01642901 - Zoledronic Acid in Acute Spinal Cord Injury Phase 3
Completed NCT01884662 - Virtual Walking for Neuropathic Pain in Spinal Cord Injury N/A
Terminated NCT01433159 - Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury Phase 2
Completed NCT01471613 - Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury Phase 1/Phase 2
Completed NCT01467817 - Obesity/Overweight in Persons With Early and Chronic Spinal Cord Injury (SCI) N/A
Completed NCT02149511 - Longitudinal Morphometric Changes Following SCI
Completed NCT00663663 - Telephone Intervention for Pain Study (TIPS) N/A
Completed NCT01025609 - Dietary Patterns and Cardiovascular (CVD) Risk in Spinal Cord Injury (SCI) Factors In Individuals With Chronic Spinal Cord Injury
Completed NCT01086930 - Early Intensive Hand Rehabilitation After Spinal Cord Injury Phase 3
Terminated NCT01005615 - Patterned Functional Electrical Stimulation (FES) Ergometry of Arm and Shoulder in Individuals With Spinal Cord Injury Phase 1/Phase 2